Want to see HK:1666 full AI Analyst Report?
Top Page
Tong Ren Tang Technologies Co
(1666)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$3.50
â–¼(-0.57% Downside)
Action:Reiterated
Date:08/06/26
The score is primarily driven by mixed financial performance: a solid balance sheet and a sharp 2025 cash-flow rebound are tempered by weakening 2025 revenue and profitability and cash-flow volatility. Valuation is a key positive (low P/E and high dividend yield), while technicals are neutral-to-soft with price below longer-term moving averages.
Positive Factors
Improving balance sheet leverage
Moderate and declining leverage plus multi-year equity growth strengthen financial flexibility. This durable improvement reduces solvency risk, supports funding for capex or working-capital needs, and gives management room to navigate cyclical downturns without forced asset sales.
Negative Factors
Sustained revenue decline
A meaningful year-over-year revenue contraction signals weakening demand or market-share loss in core categories. Persistent top-line declines impair scale economics, limit reinvestment capacity, and make it harder to absorb fixed costs, increasing execution risk over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving balance sheet leverage
Moderate and declining leverage plus multi-year equity growth strengthen financial flexibility. This durable improvement reduces solvency risk, supports funding for capex or working-capital needs, and gives management room to navigate cyclical downturns without forced asset sales.
Read all positive factors
Tong Ren Tang Technologies Co (1666) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.03B
Dividend Yield6.59%
Average Volume (3M)1.82M
Price to Earnings (P/E)11.4
Beta (1Y)0.81
Revenue Growth-13.93%
EPS Growth-25.30%
CountryHK
Employees3,801
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.23
Shares Outstanding628,704,000
10 Day Avg. Volume3,154,607
30 Day Avg. Volume1,823,827
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)0.69
Price to Sales (P/S)0.78
P/FCF Ratio3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.36
Revenue Forecast (FY)HK$6.96B
Tong Ren Tang Technologies Co Business Overview & Revenue Model
Company Description
Tong Ren Tang Technologies Co. Ltd., a company founded in 1669 and based in Beijing, People's Republic of China, maintains extensive operations across Mainland China and Hong Kong. Its primary activities center on the manufacturing and sale of tra...
How the Company Makes Money
The company makes money primarily by selling traditional Chinese medicine and related healthcare products. Its core revenue stream is product sales, which typically include (1) manufactured TCM pharmaceutical products (e.g., proprietary Chinese me...
Tong Ren Tang Technologies Co Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
74
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.73B | 6.48B | 7.26B | 6.77B | 5.99B | 5.40B |
| Gross Profit | 2.11B | 2.47B | 2.88B | 2.85B | 2.59B | 2.29B |
| EBITDA | 913.17M | 1.00B | 1.17B | 1.30B | 1.39B | 1.26B |
| Net Income | 303.31M | 396.28M | 521.79M | 590.19M | 582.89M | 507.25M |
Balance Sheet | ||||||
| Total Assets | 13.35B | 13.72B | 14.41B | 13.51B | 12.48B | 11.59B |
| Cash, Cash Equivalents and Short-Term Investments | 5.00B | 4.84B | 4.38B | 4.24B | 4.18B | 3.89B |
| Total Debt | 1.95B | 2.17B | 2.43B | 1.63B | 1.59B | 1.64B |
| Total Liabilities | 3.20B | 3.34B | 4.24B | 3.86B | 3.47B | 3.44B |
| Stockholders Equity | 7.30B | 7.34B | 7.21B | 6.89B | 6.48B | 5.98B |
Cash Flow | ||||||
| Free Cash Flow | 1.15B | 1.45B | -158.56M | 450.78M | 565.85M | 877.01M |
| Operating Cash Flow | 1.25B | 1.56B | 15.61M | 554.17M | 723.77M | 1.03B |
| Investing Cash Flow | -11.46M | 50.30M | 1.05B | -1.07B | 43.01M | -197.36M |
| Financing Cash Flow | -1.15B | -1.01B | 288.35M | -497.76M | -499.45M | -474.67M |
Tong Ren Tang Technologies Co Technical Analysis
Negative
3.52
Price Trends
3.33
Negative
3.39
Negative
3.75
Negative
Market Momentum
-0.06
Negative
45.11
Neutral
60.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1666, the sentiment is Negative. The current price of 3.52 is above the 20-day moving average (MA) of 3.19, above the 50-day MA of 3.33, and below the 200-day MA of 3.75, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 45.11 is Neutral, neither overbought nor oversold. The STOCH value of 60.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1666.
Tong Ren Tang Technologies Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$772.87M | 7.66 | 13.59% | 7.46% | 10.63% | 39.44% | |
72 Outperform | HK$4.91B | 10.64 | 11.15% | 6.31% | -20.79% | -30.04% | |
65 Neutral | HK$100.88B | 11.44 | 20.68% | 3.33% | 25.21% | 103.93% | |
64 Neutral | HK$4.03B | 11.41 | 4.14% | 6.59% | -13.93% | -25.30% | |
53 Neutral | HK$6.52B | -5.25 | -4.98% | 0.27% | -15.80% | -298.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$345.46M | 91.67 | 0.34% | 84.69% | -8.30% | -44.44% |
* Healthcare Sector Average
HK:1666
Tong Ren Tang Technologies Co
3.14
-1.56
-33.18%
HK:3613
Beijing Tong Ren Tang Chinese Medicine Co
5.90
-3.03
-33.93%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.27
-0.92
-42.01%
HK:1093
CSPC Pharmaceutical Group
8.71
-1.26
-12.64%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.33
-0.05
-13.16%
HK:0239
Pak Fah Yeow International Limited
2.45
0.15
6.38%
Tong Ren Tang Technologies Co Corporate Events
Tong Ren Tang Technologies Faces Dissolution Bid for Key Healthcare Subsidiary
Jul 14, 2026
Tong Ren Tang Technologies Co. Ltd. has disclosed that its 51%-owned subsidiary, Beijing Tong Ren Tang Xing An Healthcare Technologies Co., Limited, faces a dissolution application filed by its 49% shareholder, Beijing Dekang Xinrui Trading Co., L...
Tong Ren Tang Technologies Revamps Board Secretariat and Governance Roles
Jul 9, 2026
Tong Ren Tang Technologies Co. Ltd. announced board-level administrative changes effective 9 July 2026, including the resignation of Mr. Han Guan Zhao as secretary of the Board and the cessation of Ms. Ma Wing Yee’s role as authorised repres...
Tong Ren Tang Technologies Sets Final 2025 Dividend and Clarifies Tax Treatment for H Shareholders
Jun 12, 2026
Tong Ren Tang Technologies Co. Ltd. has declared a final ordinary dividend of RMB 0.18 per share for the financial year ended 31 December 2025, with shareholders approving the payout on 12 June 2026. The dividend for H share holders will be paid i...
Tong Ren Tang Technologies Wins Shareholder Backing for 2025 Results and Dividend
Jun 12, 2026
Tong Ren Tang Technologies Co. Ltd. reported that all resolutions proposed at its 2025 annual general meeting, held in Beijing on 12 June 2026, were approved by shareholders via poll with overwhelming majorities. Investors endorsed the audited fin...
Tong Ren Tang Wins Hong Kong Registration for New Proprietary Chinese Medicine
May 26, 2026
Tong Ren Tang Technologies announced that its subsidiary Beijing Tong Ren Tang Chinese Medicine has received a Certificate of Registration of Proprietary Chinese Medicine in Hong Kong for its Antelope Horn Powder Capsules. The registration, valid ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.